Abstracts

534 – Body Mass Index and Virologic Outcomes in Individuals on CAB+RPV LA in the OPERA Cohort

Background Cabotegravir + rilpivirine long-acting (CAB+RPV LA) is the only complete LA regimen indicated for people with HIV who are virologically suppressed (HIV-1 RNA viral load [VL] <50 copies/mL) on a stable antiretroviral regimen. Previous analyses from this cohort showed that 30% of individuals initiating CAB+RPV LA had BMI of ≥30 kg/m2. This analysis assessed baseline characteristics, persistence,…

313 – Lauric Acid Enhances T-Cell Recovery, Reduces Inflammation, and Impacts the HIV Reservoir on ART

Background Persistent inflammation is common in people living with HIV (PLWH) despite suppressive antiretroviral therapy (ART). Lauric acid (LA), a medium-chain dietary fatty acid, may enhance immune recovery and reduce inflammation. Methods In a randomized, placebo-controlled clinical trial, 45 PLWH on stable ART received daily oral 3g LA (n=15), 1.5g LA (n=15) or placebo (n=15)…

871 – Depression, Anxiety, and Viral Suppression Among Adolescents and Young Adults in 9 African Countries

Background Adolescents and young adults living with HIV (ALWH) have the lowest viral suppression rates of all age groups. Depression and anxiety may undermine treatment outcomes yet have not been systematically assessed among ALWH in Africa at scale. Using population-representative data, we estimated the prevalence of depressive and anxiety symptoms among ALWH and their association…

610 – Glecaprevir/Pibrentasvir Combination Within Individual Particles Drives Optimal LAI Performance

Background We previously described intramuscular (IM) preclinical pharmacokinetics (PK) of a long-acting injectable (LAI) formulation of glecaprevir (G) and pibrentasvir (P) as a potential one-shot cure for HCV. Longer terminal half-life extension for G and higher overall exposure of P was observed when both drugs were administered as a fixed dose combination (FDC) compared to…

1066 – High Acceptability and Safety of Out-of-Hospital Cabotegravir and Rilpivirine Administration (HOLA)

Background Long-acting (LA) injectable antiretroviral therapy (ART) with cabotegravir and rilpivirine (CAB+RPV) improves convenience and quality of life for people with HIV (PWH). While its efficacy and safety have been demonstrated in clinical trials and real-world studies, administration is often limited to hospital settings, which may pose logistical barriers. The HOLA study evaluates the acceptability…

1067 – HIV Prevention Social Vaccine in Cameroonian Educational Communities

Background In Cameroon, the prevalence of HIV has declined from 5.5% to 2.7% in the general population. However, HIV incidence remains worrying among adolescents and young people, comprised of students attending primary and higher schools. This necessitates innovative community-based interventions to improve prevention in these target-populations. We herein report on HIV-prevention, HIV prevalence and associated-factors…

883 – A Fine-Tuned Large Language Model for Predicting Provincial HIV Case Increases

Background Short-horizon, province-level signals of HIV case increases can help anticipate testing capacity and targeted outreach. Conventional time-series and machine-learning methods typically demand long look-back windows and numerous predictors for both training and inference. We examined whether a low-rank adaptation (LoRA)-adapted pretrained large language model (LLM) can forecast short-term increases using limited observations. Methods We used…